Clinical Trial Search

Primary: Incidence of Any Adjudicated Bleeding Events — 33.3; 14.3; 22.7; 40.0 percentage of subjects with bleeds

Primary: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 — 93.4; 88.1 percentage of participants — p=0.066

Primary: Detection of Any Adenoma at the End of the Study — 17; 53; 121; 76 participants

Primary: Percentage of Participants With a Reduction of Mean GH Levels to < 2.5 µg/L and Normalization of Sex- and Age-adjusted IGF-1. — 15.4; 20.0; 0 percentage of participants…

Primary: Percentage of Participants Achieving a Psoriasis Area and Severity Index Greater Than or Equal to 75% Reduction (PASI 75) Response at Week 12 — 11.5; 77.8 percentage of…

Primary: Success Rate — 38.4; 11.6 Percentage of participants — p=<0.001

Primary: Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths and Discontinuations Due to AEs — 0; 0; 0; 0 participants

Primary: Change From Baseline to Week 12 in Average Daily Normalized "Off" Time — -4.04; -2.14 hours — p=0.0015

Primary: Success Rate — 40.1; 18.8 Percentage of participants — p=<0.001

Primary: Change From Baseline to 26-week Endpoint in Glycosylated Hemoglobin (HbA1c) — -0.78; -0.71; -0.56 percentage of glycosylated hemoglobin — p=<0.001

Primary: Humoral Immune Response in Terms of Haemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Vaccine Influenza Strains — 61.0; 65.7; 337.4; 207.5 Titer

Primary: Wender Reimherr Adult Attention Deficit Disorder Scale — 11.0; 17.9 units on a scale — p=.001

Primary: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths and Discontinuations Due to AEs — 8; 7; 111; 108 participants

Primary: Change From Baseline to 52 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c) — -1.08; -0.76; -0.63 percentage of glycosylated hemoglobin — p=<0.001

Primary: Change From Baseline to Week 12 in Average Daily Normalized "Off" Time — -4.04; -2.14 hours — p=0.0015